Sign in
CompletedPhase 3

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Key facts

Who runs it
Takeda
Where
Japan8 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
12 people enrolled
Started
27 Apr 2021
Ended
25 Apr 2024
Type of study
Interventional
Treatments tested
  • IGSC 20% infusion
Record updated
20 January 2025

Who can take part

Age
2 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Participant has completed or is about to complete Takeda Clinical Study TAK-664-3001; A participant is considered to have completed Study TAK-664-3001 successfully if they fulfill the following criterion: Completed Epoch 2, in which IGSC, 20% is administered weekly (completion of Epoch 3, in which IGSC, 20% is administered biweekly, is not mandatory for participation in TAK-664-3002 study)
  • Written informed consent is obtained from either the Participant or the Participant's legally authorized representative prior to any study-related procedures and study product administration
  • Participant is willing and able to comply with the requirements of the protocol

Who cannot take part

  • Participant is scheduled to participate in another non-Takeda clinical study involving an Investigational Product or device-used-in-clinical-trial in the course of this study
  • Participant has developed a new serious medical condition during participation in Study TAK-664-3001 such that the Participant's safety or medical care would be impacted by participation in the extension study TAK-664-3002
  • If a female of childbearing potential, Participant is pregnant or has a negative pregnancy test but does not agree to employ adequate birth control measures for the duration of the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with IGCS, 20% in this study.

Read full original descriptionShow less

The main aim of this study is to check for side effects from long-term treatment with IGSC, 20% . This medicine is not yet licensed in Japan, so participants will be treated with IGSC, 20% until it becomes commercially available.

The group in the trial

  • IGSC, 20%Treatment being tested

    Participants who completed Epoch 2 of core study TAK-664-3001 (NCT04346108), received between 50 to 200 mg/kg of Immune globulin subcutaneous (IGSC) infusion, 20% infusion once a week (Epoch 2 regimen) and 100 to 400 mg/kg of IGSC infusion, 20% biweekly (Epoch 3 regimen) until the study drug becomes commercially available.

    Treatment: IGSC 20% infusion

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
Record updated
20 January 2025